News

Targeted Oncology2h
ALLELE Trial Confirms Clinical Activity of Tabelecleucel in Lymphoproliferative Disease
Tabelecleucel shows promising efficacy in treating EBV-positive PTLD, offering hope for patients resistant to previous ...